Skip to content

Altimmune, Inc

ALTNASDAQ · Pharmaceutical Preparations

Price

FilingsNewest: 8-K, Director or officer changeSep 29 →Insiders6 insiders bought $325,870 in 10 open-market buys. No sales.→HoldersBlackRock 10.5%Deep Track Capital 9.9%State Street 6.2%→Financing →PeersClosest companies: FULC, SEPN, SYRE→

From the filings

Figures

Revenue: $41,000last 12 months
Net income: −$91.8Mlast 12 months
Operating cash flow: −$71.6Mlast 12 months
Cash and equivalents: $63.0Mat the last balance sheet
Total debt: $34.7Mat the last balance sheet
Shares outstanding: 194.5M shareson issue

Every year and quarter →

Filings, newest first

All filings →